Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Sodium–glucose cotransporter 2 (SGLT2) inhibitors belong to a novel class of glucose-lowering medications that reduce plasma glucose concentrations by inhibiting glucose reabsorption by the kidney, inducing glucosuria. Their actions encompass reductions in HbA
1c
, fasting and postprandial blood glucose levels, body weight and BP. To date, em...
Alternative Titles
Full title
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2091820669
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2091820669
Other Identifiers
ISSN
0012-186X
E-ISSN
1432-0428
DOI
10.1007/s00125-018-4663-6
